ArticleInternational journal of hematology2019

Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy.

Norifumi Tsukamoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.